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It is the aim of this article to review and appraise avail-
able data on treatments for alopecia areata (AA) accord-
ing to the demands of evidence based medicine. Studies
evaluating the e⁄cacy of a treatment for AA should in-
clude appropriate controls, use cosmetically acceptable
hair regrowth as a parameter for treatment success, in-
clude patients with AA totalis, universalis or extensive
patchyAA, and exclude patients su¡ering from AA for
less than 3 months. Moreover, the treatment must be
safe over a prolonged period of time. Among the var-
ious therapeutic approaches presently available for AA,
only treatment with contact sensitizers such as diphe-
nylcyclopropenone or squaric acid dibutylester has been
shown to be e¡ective in studies that ful¢ll these criteria.
Improved future treatments may be immunosup-
pressive or immunomodulatory targeting of the auto-
immune pathogenesis of AA, or they may otherwise
protect hair follicles from the injurious e¡ects of
in£ammation. Such possible future therapeutic ap-
proaches include the incorporation of immunomodula-
tory agents into liposomes as an improved vehicle;
inhibition of apoptosis mediated by the Fas-FasL sys-
tem; inhibition of the lymphocyte homing receptor
CD44v10; induction of tolerance. Key words: Evidence
based medicine/T-cell/autoimmune disease/hair follicle. JID
Symposium Proceedings 8:12 ^17, 2003
A
lopecia areata (AA) is characterized by patchy or
sometimes total loss of scalp or body hair with wax-
ing and waning of bald areas. Although acute phases
of hair loss are followed by spontaneous hair re-
growth in most patients, the disorder may persist
for many years or even for life when severe. But even in these
cases hair loss is potentially reversible, because the disease usually
does not result in destruction of hair follicles or scarring. There-
fore, every patient su¡ering from AA has the right to be treated
according to the rules of evidence based medicine (EBM)
(Epstein, 2001), which is the process of systematically ¢nding, ap-
praising, and using contemporaneous research ¢ndings as the ba-
sis for clinical decisions (Rosenberg and Donald, 1995). It is the
aim of this review to assess critically the published studies dealing
with various therapies for AA and to determine which are most
e¡ective and safe.
There are about 600 publications, not to mention anecdotal
reports, about treatment of AA published in the last 30 years.
But ‘‘the practice of evidence based medicine means integrating individual
clinical expertise with the best available external clinical evidence
from systematic research’’ (Sackett, 1996). Therefore, we de¢ne four
criteria that help to identify publications that are the best available
evidence:
1 Because AA is characterized by episodes of hair loss and re-
growth and the spontaneous course of the disease cannot be
predicted, any treatment study has to distinguish between
spontaneous remission and therapeutic response. This is possi-
ble in a double-blind, placebo controlled study, which must
include a large number of patients to yield statistically signi¢-
cant results. In topical approaches, however, the strictest criter-
ion to exclude spontaneous remission is to treat every patient
on one half of the scalp only. Only patients with substantially
better hair growth on the treated side are allowed to be re-
garded as successfully treated. In patchy AA a large patch has
to be treated unilaterally, because treatment of one patch with
another patch as control does not exclude spontaneous hair re-
growth. Half-side treatment can even be performed in a dou-
ble-blind form by treating one side with the drug and the
other with a placebo.
2 Hair regrowth in the treated area has to be substantial and cos-
metically acceptable, because ‘some regrowth’ is not of practical
bene¢t to the patient.
3 The prognosis of AA is in£uenced by several factors, in parti-
cular by the type and extent of AA (Weise et al, 1996;Wiseman
et al, 2001) with a worse prognosis for patients with AA totalis
or universalis or with extensive patchyAA as compared to lim-
ited patchy AA. According to the rules of EBM, we cannot
accept the auxiliary hypothesis of a dichotomy between mild
AA that can be ‘successfully’ treated with various doubtful
approaches, such as topical corticosteroids, minoxidil or anthra-
lin, and severe AA that cannot be treated with these drugs.
Rather there is convincing evidence that these topical
approaches do not exert any inhibitory e¡ect on a possible
spontaneous regrowth. Hence, studies evaluating a treatment
for AA should preferably include patients with AA totalis, AA
universalis and extensive patchyAA (425% scalp hair loss).
4 The duration of the disease also has an in£uence on its prog-
nosis. Because hair regrowth is more likely in AA of short
duration, patients to be included in a study should have had
AA for more than 3 months.
5 Any treatment has to be suitable for long-term therapy, because
AA is a disease that can persist for many years or even for life.
Hence, all therapeutic approaches showing severe side-e¡ects
in the long run are inappropriate.
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In summary, a study according to the demands of EBM should
ful¢ll the following criteria:
1 Controlled study (placebo controlled with statistically signi¢-
cant results, or unilateral treatment)
2 Majority of patients with AA totalis, AA universalis or exten-
sive patchyAA (425% hair loss)
3 Duration of disease for more than 3 months
4 Cosmetically acceptable hair regrowth
5 No serious side-e¡ects
CURRENT TREATMENTS FOR ALOPECIA AREATA
Immunosuppressive Treatments
Corticosteroids Among their various anti-in£ammatory e¡ects
that are beyond the scope of this article, corticosteroids are
known to exert a strong inhibitory e¡ect on the activation of T
lymphocytes. In consideration of the TH-1 mediated immune at-
tack on the hair follicle in AA, corticosteroids are potentially
good candidates for the treatment of this disease.
Topical, intralesional, and systemic corticosteroids have been
used to treat AA, with di¡erent rates of success and side-e¡ects.
Topical corticosteroids Topical treatment with corticosteroid
creams, ointments or lotions are frequently used for AA. How-
ever, only two placebo-controlled studies reported a treatment
response (Pascher et al, 1970; Leyden and Kligman, 1972), but both
studies do not ful¢ll the other criteria for evidence based treat-
ment of AA. Furthermore, both studies were performed in the
1970s and they have not been con¢rmed by others over the last
30 years (Weitgasser, 1968; Verbov, 1973; Lehnert, 1974; Montes,
1977). Only one placebo-controlled study with an appropriate
number of patients has been performed to date, but the rate of
treatment success was not statistically signi¢cant (Charuwichitra-
tana et al, 2000).
The failure of topical corticosteroids is most likely due to the
insu⁄cient penetration of topically applied drugs from oint-
ments, creams or lotions into the hair bulb. Improving penetra-
tion by occlusion has been tried without success (Lehnert, 1974).
Considering the lack of treatment response and the side-e¡ects of
topically applied corticosteroids, we conclude that topical corti-
costeroids are not an e¡ective method of treating AA.
Intralesional corticosteroids Intralesional injection of corticosteroid
crystal suspensions, primarily triamcinolone acetonide, has been
used to treat AA for more than 40 years (Kalko¡ and Macher,
1958). Several studies reported hair regrowth at the site of injec-
tion in the majority of cases (Kalko¡ and Macher, 1958; Oren-
treich et al, 1960, Fˇl˛p and Vajda, 1971; Porter and Burton, 1971;
Abell and Munro, 1973; Frentz, 1977). Most of these studies tried
to exclude spontaneous hair regrowth by comparing the injected
sites of the scalp with uninjected areas, especially in alopecia to-
talis. However, in practice, it is impossible to treat the whole scalp
by intralesional injections of corticosteroids and so this treatment
is only indicated in patchy AA with longstanding bald areas.
Apart from the painful procedure of injection, permanent atro-
phy can occur after injection. Taken together, intralesional injec-
tion of corticosteroids is a reasonable treatment in exceptional,
selected cases of longstanding small patches of AA, but has
potentially serious side-e¡ects.
Systemic corticosteroids AA has been treated with systemic corti-
costeroids since 1952 (Dillaha and Rothman, 1952).Whereas, initi-
ally, oral corticosteroids were used daily or every other day for
several months, this continuous use of corticosteroids is obsolete
today. Doses that are required to maintain hair regrowth in AA
are between 30 and 150 mg daily, giving rise to unacceptable side-
e¡ects such as hypertension, diabetes, immunosuppression, osteo-
porosis and proneness to thrombosis.
Since 1975 several authors have performed pulsed administra-
tion of corticosteroids in single doses, given once monthly in or-
der to reduce the side-e¡ects of corticosteroids to an acceptable
level, but all studies which noted hair regrowth, were uncon-
trolled and the majority of patients had patchyAA (Perriard-Wol-
fensberger et al, 1993; Sharma, 1996; Friedli et al, 1998; Sharma
and Muralidhar, 1998; Seiter et al, 2001). Moreover, other studies
reported treatment failure after corticosteroid pulse therapy
(Burton and Shuster, 1975; Schulz et al, 1996). Controlled studies
should be conducted to prove the e⁄cacy and long-term value
of this treatment. Especially the e⁄cacy in interrupting acute
phases of rapid hair loss by pulsed administration of oral corticos-
teroids should be investigated. Based on the data presently avail-
able, pulsed administration of corticosteroids for AA cannot be
recommended.
PUVA Several studies have examined treatment of AA with
PUVA using either oral 8-methoxypsoralen (8-MOP) with
ultraviolet A radiation (UVA) on the scalp or the whole body,
or topical application of 8-MOP and UVA radiation on the
scalp, including one study with topical application of psoralen
via the PUVA-turban (Claudy and Gagnaire, 1983; Lark˛ and
Swanbeck, 1983; Lassus et al, 1984; Mitchell and Douglass, 1985;
Healy and Rogers, 1993; Taylor and Hawk, 1995; Behrens-
Williams et al, 2001). Some studies seemed to have good results
(Claudy and Gagnaire, 1983; Lassus et al, 1984; Healy and Rogers,
1993; Taylor and Hawk, 1995; Behrens-Williams et al, 2001), but
there were no controls in any of the studies. Moreover, there
were a large number of recurrences (between 30% and 50% of
successfully treated patients) after initial hair regrowth, which
strongly decreased the e⁄cacy of PUVA treatment for AA
(Claudy and Gagnaire, 1983; Lassus et al, 1984; Healy and Rogers,
1993; Taylor and Hawk, 1995). The high number of recurrences is
most likely due to the fact that regrown hair inhibits UVA
radiation from reaching the skin. Technical improvements such
as a comb that emits UVA radiation have been tried, but so far
no results have been reported. Unfortunately, continuous hair
regrowth after an initial response has to be actively maintained
for several years in most cases. Because of an increased risk for
skin malignancies after long-term therapy, PUVA cannot be
recommended for AA, even if technical improvements such as a
UVA-comb should ultimately prove to be e¡ective.
Immunomodulatory treatments
Diphenylcyclopropenone and squaric acid dibutylester AA
has been treated with contact sensitizers for more than 20 years.
Dinitrochlorobenzene (DNCB) was the ¢rst to be used (Happle
and Echternacht, 1977), but because it has been shown to be
mutagenic in the Ames test, it can no longer be recommended
(Happle, 1979, 1985). Today diphenylcyclopropenone (DCP) or
squaric acid dibutylester (SADBE), which are not mutagenic in
the Ames test, are widely used in Europe and in Canada.
Treatment Treatment with contact sensitizers is preceded by sen-
sitization of the patient with 2% DCP solution on a small area of
the scalp. Two weeks later, treatment is initiated by applying a
0.001% DCP solution, followed by weekly applications of in-
creasing concentrations until a mild eczematous reaction is ob-
tained. In this way, an appropriate eliciting concentration of
DCP is identi¢ed for each patient. This concentration is then ap-
plied once a week to induce a mild eczematous reaction charac-
terized by itching and erythema, without blistering or oozing.
SADBE is used in those patients who become tolerant to DCP.
It is applied in the same way and shows similar rates of
response.
Initial hair regrowth is usually visible after 8^12 weeks. Treat-
ment must be continued once weekly until complete hair re-
growth is obtained. Treatment intervals are then decreased, and,
eventually treatment may be discontinued. However, if relapse
occurs, treatment can be restarted immediately to stop further
progression of AA and to induce renewed hair growth. At the
Department of Dermatology, University of Marburg, treatment
is always applied initially to half of the scalp and the other half
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is left untreated to exclude spontaneous hair regrowth coincident
with treatment initiation. Treatment is continued on both sides
only after the treated side has shown a response that is better than
that of the untreated side.
Side-e¡ects Mild eczematous reactions and enlargement of retro-
auricular lymph nodes are desired reactions and inherent to treat-
ment. These are usually well tolerated if patients are informed
that they are desired for the therapeutic e¡ect. Undesired side-ef-
fects are noted in 2^5% of patients (Ho¡mann and Happle, 1996).
Vesicular or bullous reactions sometimes occur at the beginning
of treatment before appropriate individual concentrations have
been determined. Dissemination of allergic contact dermatitis,
urticarial or erythema multiforme-like reactions may also occur
(Perret et al, 1990), but these can be treated successfully with topi-
cal corticosteroids. Pigmentary disturbances such as postin£am-
matory hyperpigmentation with spotty hypopigmentation
(‘dyschromia in confetti’) have been observed, especially in pa-
tients with dark skin, but these have resolved within 1years after
discontinuing treatment in most instances (van der Steen and
Happle, 1992; Ho¡mann and Happle, 1996). Apart from these
acute and subacute side-e¡ects, no long-term side-e¡ects have
been reported after 18 years of DCP (21 years of SADBE) treat-
ment worldwide of about 10000 patients, including children.
However, it should be borne in mind that DCP and SADBE are
not approved therapeutic substances.
Studies More than 25 studies have been performed to test the
e⁄cacy of treating AA with contact sensitizers. The most
signi¢cant controlled studies are listed in Table 1. In contrast to
corticosteroid and PUVA treatment studies, the majority of stu-
dies with contact sensitizers were controlled, with most using an
untreated side of the scalp as a control.When comparing response
rates for various modalities, one should bear in mind that sponta-
neous regrowth is excluded in these controlled, within-patient
studies, but not in the uncontrolled ones. Response rates of
treatment with contact sensitizers varies from 29% to 78% (see
Table). The di¡erences may be explained in part by the di¡erent
extent and duration of AA prior to treatment for the patients in
each study, and in part by di¡erences in methods of treatment.
However, the median response rate of all studies is 51%, render-
ing contact sensitizers an e¡ective therapeutic tool for AA accord-
ing to the demands of EBM.
How contact sensitizers act in treating AA is still not fully un-
derstood, but recent studies have contributed useful information.
This has been discussed in detail elsewhere (Freyschmidt-Paul
et al, 2001; Happle et al, 1986). Brie£y, the speci¢c interaction
of CD8þ/CD4þ T lymphocytes with dendritic cells and
MHC class I/MHC class II positive hair follicle keratinocytes
leading to AA may be interrupted by treatment with a contact
sensitizer, by introducing tolerogenic cytokines T-cells or cyto-
kines.
Other treatments
Irritant contact dermatitis ^ anthralin While treatment of AA
using allergic contact dermatitis has proven to be e¡ective,
treatment of AA with an irritant contact dermatitis has
never been shown to be successful in a controlled study.
In a half-side controlled study, using 0.1% anthralin to produce
a mild irritant contact dermatitis, no di¡erences between treated
and untreated sides were observed (Nelson and Spielvogel,
1985). Therefore, anthralin cannot be recommended for treatment
of AA.
Minoxidil Because the antihypertensive agent minoxidil causes
hypertrichosis as a side-e¡ect,Weiss et al attempted to use it as a
treatment for various forms of hair loss, including alopecia areata
(Weiss et al, 1984). But none of the studies that have claimed suc-
cess with minoxidil ful¢llled the criteria of evidence based treat-
ment (Weiss et al, 1984; Fiedler-Weiss et al, 1986; Price, 1987a, b;
Rancho¡ et al, 1989).
Six other placebo-controlled studies performed by various
groups failed to show statistically signi¢cant di¡erences between
the placebo and minoxidil (White and Friedmann, 1985; Frentz,
1984; Maitland et al, 1984;Vanderveen et al, 1984;Vestey and Savin,
1986; Fransway and Muller, 1988). In three of these studies cosme-
tically acceptable hair regrowth was not observed in any patient
(White and Friedmann, 1985; Vanderveen et al, 1984; Fransway
and Muller, 1988).
When the pathophysiological demands of AA are considered,
it is not surprising that minoxidil does not induce hair regrowth,
because it exerts no e¡ect on the extent or composition of the
perifollicular in¢ltrate (Khoury et al, 1992). A nonspeci¢c action
of minoxidil is very unlikely to induce hair regrowth, because
each growing anagen hair follicle will be attacked by the
Table1. Treatment of AAwith contact sensitizers, studies according to the demands of EBM
Clinical form of AA (number of patients)
Reference
Contact
Sensitizer
Patchy
AA
AA
totalis
AA
universalis
Controlled
study
Number of
patients
Cosmetically acceptable
hair regrowth
Happle et al, 1983 DCP 5 22 0 Yes (ULT) 27 68
Happle et al, 1984 DCP 8 37 0 Yes (ULT) 45 58
Ochsendorf et al, 1988 DCP 18 8 1 Yes (ULT) 27 37
Macdonald Hull and Norris, 1988 DCP 8 20 0 Yes (ULT) 28 29
Monk, 1989 DCP 0 14 Yes (ULT) 14 43
Steen van der, et al, 1991 DCP 78 32 29 Yes (ULT) 139 50.4
Macdonald Hull et al, 1991b DCP 4 8 0 Yes (ULT) 12 children 33
Macdonald Hull et al, 1991a DCP 33 45 0 Yes (ULT) 78 55
Hoting et Boehm, 1992 DCP 11 20 14 Yes (ULT) 45 51
Gordon et al, 1996 DCP 12 36 0 Yes (ULT) 48 38
Schuttelaar et al, 1996 DCP 10 16 0 Yes (ULT) 26 children 32
Weise et al, 1996 DCP 43 22 40 Yes (ULT) 105 48
Cotellessa et al, 2001 DCP 14 42 0 Yes (ULT) 56 48
Wiseman et al, 2001 DCP 113 35 0 Yes (ULT) 148 77,9
Happle et al, 1980 SADBE 26 27 0 Yes (ULT) 53 70
Case et al, 1984 SADBE 11 10 Yes (ULT) 21 52
Caserio 1987 SADBE 2 5 7 Yes (ULT) 14 29
Micali et al, 1996 SADBE 129 8 0 Yes (ULT) 137 64
ULT, unilateral treatment, untreated side serves as control.
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immune response if there is no immunomodulation or immune
suppression (Fig 1).
In summary, minoxidil is not useful in treating AA.
EXPERIMENTALTHERAPEUTIC APPROACHES FOR
ALOPECIA AREATA
FK506 FK506 (tacrolimus) is an immunosuppressive agent that
can be applied topically to the skin. FK506 suppresses IL-2
production and release in activated T cells. Subsequently,
activation and proliferation of T cells are inhibited (Schreiber
and Crabtree, 1992). Therefore, FK506 is a promising candidate
for the treatment of AA. Moreover, topical application of FK506
also has a hair growth stimulatory e¡ect, independent of its T cell
suppressive e¡ect (Yamamoto et al, 1994).
In the DEBRmodel of AA and in AA a¡ected C3H/HeJ mice,
topically applied FK506 induces hair regrowth (McElwee et al,
1997; Freyschmidt-Paul et al, 2001), accompanied by reduced
peri- and intrafollicular in¢ltrates of CD4þ and CD8þ T cells
and decreased expression of MHC class I, MHC class II and
ICAM-1 on hair follicle epithelium. These encouraging results
obtained in animal models suggested that topical application
of FK506 could be e¡ective in the treatment of human AA.
However, our own patients topically treated with tacrolimus did
not show any bene¢t. This is most likely due to the insu⁄ciency
of the vehicle to transport FK506 to the hair bulb.
FUTURE THERAPEUTIC APPROACHES
AA is considered to be a T cell mediated autoimmune disease of
the hair follicle (McElwee et al, 1999; Freyschmidt-Paul et al, 2001),
but the detailed pathogenesis of AA is thus far poorly under-
stood. Therefore, it is unlikely that a treatment inhibiting the on-
set of AA will be developed in the foreseeable future. Rather,
future therapeutic approaches should focus on limiting the ex-
pression of the disease by down-regulating autoreactive cells in
the lymphocytic in¢ltrate by an immunosuppressive or immuno-
modulatory action or by protecting the hair follicle from the in-
jurious e¡ects of the in£ammation.
In developing new treatments for AA, the nature of the disease
must be considered. As outlined above, therapeutic approaches
must be suitable for long-term therapy and should not cause se-
vere side-e¡ects. Because the in£ammatory process prevails in
and around the bulbar region of the hair follicle, any e¡ective
drug must act in this region.When applied topically, it must pe-
netrate into the subcutaneous fatty tissue. Otherwise it has to be
given systemically.
Macrolides of the Ascomycin Type Out of the group of
macrolides of the ascomycin type, topically applied SDZ ASM
981 has been used successfully to treat psoriasis and allergic
contact dermatitis (Paul et al, 2000). It inhibits the synthesis of
Th1 and Th2 cytokines. Because the pathogenesis of AA is Th1
mediated, topical SDZ ASM 981 may be a candidate for AA.
Controlled studies to challenge this hypothesis have not been
reported.
Liposomes Another novel approach in treating AA is to create
a vehicle that allows penetration to the subcutaneous fat where
the bulbs of anagen hair follicles are located and where the
pathomechanism takes place. Such a vehicle could be used to
carry, for example, a steroid to the peribulbar lymphocytic
in¢ltrate, thus making topical steroids, which are ine¡ective
in current formulations, a useful treatment. Other immuno-
suppressive agents, such as FK506, might be e¡ective in such a
vehicle, also. At present, liposomes seem to be the best candidate
as a vehicle topical treatment. Topically applied liposomes have
been shown to deliver melanin, proteins, genes and various
small molecules selectively to hair follicles and hair shafts
of mice in vivo (Li and Ho¡man, 1997). Liposome-targeting of
molecules to human hair follicles has been demonstrated in
human scalp in histoculture (Li and Ho¡man, 1995). However,
future experiments have to show whether liposomes are able to
deliver molecules to the hair bulb in human scalp in vivo.
Anti-CD44v10 antibodies Our group has shown that the
developement of AA in the C3H/HeJ mouse can be inhibited
by application of an anti-CD44v10 antibody (Freyschmidt-Paul
et al, 2000). This antibody most likely inhibits CD44v10
mediated homing of CD8þ T cells into the skin. Therefore,
application of anti-CD44v10 antibodies might be a therapeutic
tool to inhibit the development of AA. However, such
antibodies have so far never been used in humans, and nothing
is known about their side-e¡ects.
Inhibition of the Fas-FasL system Induction of hair follicle
apoptosis by the Fas-FasL system seems to be involved in the
pathogenesis of AA (Bodemer et al 2000; 1). Therefore, inhibition
of the Fas-FasL system might protect hair follicles from injury
caused by the in£ammatory in¢ltrate. However, such treatment
could only be applied topically and speci¢cally limited to hair
follicles, because systemic inhibition would disturb essential
control mechanisms of lymphocyte homeostasis.
Figure1. Evidence for complete ine¡ectiveness of topical minoxi-
dil in AA.This 12-year-old girl applied 3% minoxidil to her hairless scalp.
After 4 months, conspicuous hair growth was induced on her una¡ected
forehead, whereas the a¡ected scalp remained completely bald (courtesy
of Dr ClausW. Meisel, Nuremberg, Germany).
1Freyschmidt-Paul P, McElwee K, BotchkarevV, Sundberg J, Happle R,
Ho¡mann R:The role of Fas and Fas Ligand in alopecia areata of C3H/HeJ
mice. J Invest Dermatol 117:431 2001 (abstr.)
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Tolerance While the above-mentioned therapeutic approaches
target symptoms, the induction of tolerance to autoimmune
diseases comes close to a causal treatment. At present the
best understood way to induce tolerance is through oral
administration of an antigen. Studies in rheumatoid arthritis
suggest that induction of oral tolerance is a safe and e¡ective
(Garcia and Weiner, 1999). The major problem in developing a
protocol for induction of tolerance in AA is to ¢nd a suitable
antigen, because at present the autoantigen of AA is unknown.
One possibility to circumvent this problem is to use an antigen
that is found in the hair follicle close to the morphological
location of the original autoantigen. Induction of oral tolerance
against this antigen would lead to the development of
regulatoryT cells that migrate to a target tissue (the hair follicle)
and secrete antigen-nonspeci¢c cytokines after being triggered
with the fed antigen in the hair follicle again. These cytokines,
suppress in£ammation in the microenvironment where the
fed antigen is localized. This ‘bystander suppression’ has been
demonstrated to be e¡ective in various animal models of auto-
immune diseases such as experimental autoimmune encephalo-
myelitis (EAE), arthritis, and diabetes (Garcia andWeiner, 1999).
The immunosuppresion after induction of tolerance is restricted
to the site where the antigen is located and systemic immuno-
suppression can be avoided.
CONCLUSION
AA is today considered to be caused by aT-cell mediated autoim-
mune attack of the hair follicle. According to the rules of evi-
dence based medicine, treatment with contact sensitizers such as
DCP or SADBE is the only approach with proven e¡ectiveness.
All other methods presently available are either completely in-
e¡ective, ine¡ective in the long run, or associated with unaccep-
table side-e¡ects. Hence, treatment with potent contact sensitizers
is presently the best available approach for AA. Pulsed admini-
stration of oral corticosteroids has so far not been tested accord-
ing to the rules of evidence based medicine, but this should be
performed in the future. As long as no causal treatment is avail-
able, future approaches should focus on a more speci¢c targeting
of the underlying pathomechanism with a topical action around
the hair bulbs and without serious side-e¡ects. Possible new
therapeutic developments may include incorporation of drugs in
liposomes, macrolides of the ascomycin type, anti-CD44-v10
antibodies, inhibition of the Fas-FasL system, induction of
tolerance.
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